International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study
Journal of the European Academy of Dermatology and Venereology · 2026-09 · 40 (9) · 1449-1459
DOI: 10.1111/jdv.70447 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 21.04.2026. Verfasst von C A M van Riel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Drug Tapering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Academy of Dermatology and Venereology.
Abstract (Originalsprache)
Background
Dose reduction (DR) of biologics for psoriasis is already applied in clinical practice but without clear guidelines, while dermatologists addressed the need for guidance. An international consensus may contribute to optimal implementation of biologic DR in clinical psoriasis practices.
Objectives
This consensus study aims for international consensus on DR of biologics in adult patients with psoriasis among dermatologists worldwide.
Methods
An international, modified eDelphi consensus study was performed among dermatologists worldwide. A total of 11 statements on biologic DR were generated by the international steering committee, based on a previous literature review. Invitations were distributed via international dermatological societies. Participants rated their level of agreement per statement on a 9‐point Likert scale. A maximum of three consensus rounds and one (digital) consensus meeting were expected. Statements reached consensus if ≥70% agreed and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Division of Dermatology and Venereology, Department of Pathology and Immunology, and University Hospitals of Geneva, University of Geneva, Geneva, Switzerland.
- Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
- Department of Dermatology, Amsterdam Public Health/Infection and Immunology, Amsterdam, The Netherlands.
- Dutch Psoriasis Patients Federation ('Psoriasispatiënten Nederland'), Nijkerk, The Netherlands.
- International Federation of Psoriatic Disease Associations, Bromma, Sweden.
ORCID-Profile: C A M van Riel, J L W Lambert, E M G J de Jong, J M P A van den Reek
Förderung
- European Academy of Dermatology and Venereology
Zitieren
APA
van Riel, C. A. M., Boehncke, W. H., Lambert, J. L. W., Spuls, P. I., van der Schoot, L. S., van Ee, I., de Jong, E. M. G. J., van den Reek, J. M. P. A., & eDelphi consortium (2026). International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study. Journal of the European Academy of Dermatology and Venereology, 40(9), 1449-1459. https://doi.org/10.1111/jdv.70447
Vancouver
van Riel CAM, Boehncke WH, Lambert JLW, Spuls PI, van der Schoot LS, van Ee I, et al. International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study. Journal of the European Academy of Dermatology and Venereology. 2026;40(9):1449-1459. doi:10.1111/jdv.70447
BibTeX
@article{vanRiel2026,
author = {van Riel, C A M and Boehncke, W-H and Lambert, J L W and Spuls, P I and van der Schoot, L S and van Ee, I and de Jong, E M G J and van den Reek, J M P A and eDelphi consortium, eDelphi consortium},
title = {International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {9},
pages = {1449--1459},
doi = {10.1111/jdv.70447}
}
EUVIMED